02629 MIRXES-B
MIRXES-B
MIRXES-B
| Listing Date | 2025/05/23 |
| Listing Price | 23.300 |
Subscription Result
- Subscription Rate25.51x
- Guarantee One Lot Size4 lot
- One Lot Success Rate95%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Mirxes Holding Company Limited was founded in 2014, it is a Singapore-headquartered micro ribonucleic acid technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, a, including Singapore and China. As of May 7, 2025, the Group had one Core Product, two other commercialized products, and six product candidates at pre-clinical stage.
--
According to Frost & Sullivan, the Group is a provider of effective, non-invasive and affordable blood-based miRNA test kits for the early detection of cancer and other diseases. The Group is one of the few companies globally that have obtained regulatory approval for IVD product in the molecular cancer screening industry, and it is also the world’s first and only company that has obtained regulatory approval for IVD products of molecular gastric cancer screening. The Group derived a majority of its revenue from its GASTROClearTM tests and FortitudeTM tests.
--
The Group’s Core Product, GASTROClearTM was the only approved molecular IVD product for gastric cancer screening in the global market, and had the largest market share in terms of revenue in 2023 in the miRNA-based liquid biopsy gastric cancer screening market in Southeast Asia, with a market share of 66.3%.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | Asia Pacific |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 46.62M shares |
| No. of International Offer Shares | 40.75M shares |
| No. of HK Offer Shares | 5.87M shares |
| Offer Price | $23.30 |
| Stock Code | 2629 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, CCB International Capital Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, CCB International Capital Limited, CMBC Securities Company Limited, CMB International Capital Limited, Soochow Securities International Brokerage Limited, Livermore Holdings Limited, BOCOM International Securities Limited, Platinum Broking Company Limited, Waton Securities International Limited, Alpha Win Capital Limited, Imperium International Securities Limited, Kingkey Securities Group Limited, Yuen Meta (International) Securities Limited |
TIME TABLE
| Application Period | May 15 (Thu) - noon, May 20 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 22 (Thu) |
| Result Announcement Date | On or before May 22 (Thu) |
| Result Announcement Date | On or before May 23 (Fri) |
| Dealings in Shares commence on | May 23, 2025. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $23.30 |
| Capitalization | 6.44B |
| NAV / share ($) | $3.46 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 23.3, the net proceeds raised would be HKD 880.50M, of which |
| 51% : Used for the research and development, regulatory filings and manufacturing and commercialization of our Core Product, GASTROClearTM |
| 24% : Fund ongoing and planned R&D to further develop our pipeline products |
| 15% : Strengthening and integrating “end-to-end” capabilities to capture significant commercial potential along the value chain |
| 10% : Working capital |
IPO NEWS
| 23/05/2025 16:08 |
| {New Stock}MIRXES-B(02629) ends up 28.76% at HK$30 |
| 23/05/2025 09:20 |
| {New Stock}MIRXES-B(02629) opens up 24.46% at HK$29 |
| 22/05/2025 18:35 |
| {New Stock}MIRXES-B ends up 33.91% at HK$31.2 on grey market |
| 22/05/2025 16:20 |
| {New Stock}MIRXES-B(02629) up 20.17% at HK$28 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).